Veru (VERU) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
28 Jan, 2026Executive summary
Annual Meeting scheduled for March 12, 2026, to elect six directors, ratify auditors, amend the 2018 Equity Incentive Plan, approve executive compensation, and allow adjournment if needed.
Shareholders of record as of January 14, 2026, are eligible to vote; multiple voting methods are available, including Internet, phone, and mail.
Proxy materials are distributed electronically or by mail, with instructions for requesting paper copies.
Voting matters and shareholder proposals
Proposals include: election of six directors, ratification of Cherry Bekaert LLP as auditors, amendment to the 2018 Equity Incentive Plan, advisory vote on executive compensation, and approval of adjournment if necessary.
Shareholders can submit proposals and director nominations for the 2027 meeting, subject to advance notice and by-law requirements.
Board of directors and corporate governance
Board consists of six members, with four deemed independent under NASDAQ standards.
Board committees: Audit, Compensation, and Nominating and Corporate Governance, each with defined charters and responsibilities.
All directors attended at least 75% of meetings in fiscal 2025.
Board leadership combines CEO and Chairman roles; no lead independent director.
Shareholders may communicate with the board and recommend director nominees.
Code of Business Ethics and Insider Trading Policy are in place.
Latest events from Veru
- Enobosarm-GLP-1 combo targets muscle, fat, and bone health in obesity, with pivotal data due Q4 2027.VERU
Oppenheimer 36th Annual Healthcare Life Sciences Conference26 Feb 2026 - Net loss narrowed, cash rose, and new enobosarm/semaglutide trial to launch amid going concern risk.VERU
Q1 202611 Feb 2026 - Q3 net loss narrowed, cash rose, and full enrollment reached in key obesity drug trial.VERU
Q3 20242 Feb 2026 - Leadership transition, integration focus, and strong China growth drive future profitability.VERU
Jefferies Global Healthcare Conference1 Feb 2026 - Director elections, auditor ratification, and key proposals up for vote at March 2026 meeting.VERU
Proxy Filing28 Jan 2026 - Enobosarm aims to preserve muscle and function during GLP-1-induced weight loss, with key trial data due in 2025.VERU
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026 - Enobosarm preserved muscle, increased fat loss, and improved function in older adults on GLP-1s.VERU
Study Result9 Jan 2026 - Strong clinical progress and improved financial position, but liquidity risks remain high.VERU
Q1 202524 Dec 2025 - Enobosarm combo therapy preserved muscle, boosted fat loss, and narrowed net loss.VERU
Q4 202517 Dec 2025